Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Genmab A/S Sponsored ADR (NASDAQ:GMAB) has earned a consensus rating of “Moderate Buy” from the thirteen research firms that are currently covering the company, Marketbeat reports. Three analysts have rated the stock with a hold recommendation, nine have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $39.50.

A number of equities research analysts recently weighed in on the company. Guggenheim upped their price objective on Genmab A/S from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. HC Wainwright boosted their target price on shares of Genmab A/S from $38.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, July 2nd. Truist Financial initiated coverage on shares of Genmab A/S in a research report on Wednesday, May 27th. They set a “buy” rating and a $40.00 price target for the company. New Street Research set a $43.00 price objective on shares of Genmab A/S in a research report on Wednesday, July 22nd. Finally, Weiss Ratings raised shares of Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, September 1st.

Genmab A/S Stock Down 2.5%

Shares of NASDAQ GMAB opened at $32.23 on Friday. The company has a current ratio of 2.46, a quick ratio of 2.44 and a debt-to-equity ratio of 0.81. Genmab A/S has a 12-month low of $23.62 and a 12-month high of $35.43. The firm’s 50-day moving average price is $30.92 and its 200-day moving average price is $28.24. The stock has a market capitalization of $20.10 billion, a price-to-earnings ratio of 25.38, a P/E/G ratio of 1.86 and a beta of 0.84.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Thursday, August 6th. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.17. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.12 billion. On average, equities research analysts anticipate that Genmab A/S will post 1.17 EPS for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

Several institutional investors and hedge funds have recently made changes to their positions in GMAB. CIBC Private Wealth Group LLC boosted its position in Genmab A/S by 291.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock worth $25,000 after purchasing an additional 616 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new position in shares of Genmab A/S during the 2nd quarter valued at approximately $31,000. Osaic Holdings Inc. increased its holdings in shares of Genmab A/S by 37.8% during the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after purchasing an additional 440 shares in the last quarter. V Square Quantitative Management LLC acquired a new position in shares of Genmab A/S in the 1st quarter valued at $34,000. Finally, NewEdge Advisors LLC lifted its stake in shares of Genmab A/S by 1,229.0% in the 3rd quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock valued at $38,000 after purchasing an additional 1,143 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering, developing and commercializing differentiated antibody-based medicines. The company’s research platforms include technologies designed to create human antibodies and bispecific antibodies that engage the immune system to target cancer and other serious diseases.

Genmab’s products and partnered medicines include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; Kesimpta (ofatumumab) for multiple sclerosis, developed with Novartis; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Pfizer.